From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Fulfilled/good response
Not fulfilled/good response
Severe allergic asthma
380/250
12/5
Age >6 years
403/263
0/0
A positive skin test or RAST
364/241
26/12
FEV1 <80
279/183
116/77
>2 exacerbations
384/250
11/7
Maximum dose LABAs and ICS
394/257
4/3